GLP1 Research Roundup (January 2024)

GLP1 Research Roundup (January 2024)
Photo by Patrick Tomasso / Unsplash

GLP1 Receptor Agonist drugs (Semaglutide, Ozempic, Mounjaro, Wegovy, etc) have seen extensive testing and research in the past, due to their usage by people with type 2 Diabetes.

Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work?

Check out our quick explainer

Finding all this research is hard, so here at GLP1.Guide we're trying to put together a list. Here's what we've found – most recent research first.

There was a lot of new research this month, and while many of them were meta-analyses and other kinds of commentary, there were quite a few novel approaches and interesting data to dig into.

It looks like December 2023 was quite the sleepy period for research publication (for obvious reasons), but January 2024 has picked up significantly!


GLP-1 agonists: A review for emergency clinicians

Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice

Drug Review: Tirzepatide

(Commentary) Tirzepatide - a dual GIP and GLP-1 (GLP1) receptor agonist (

Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

Pharmacotherapy for obesity: moving towards efficacy improvement

Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions – a narrative review

Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health

The effects of incretin-based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta-analysis

Glucagon-like peptide-1 receptor agonists for post-bariatric surgery weight regain and insufficient weight loss: A systematic review

Case Studies

Accidental Once-Daily Use of Dulaglutide: A Case Report

P-31 GLP1 receptor agonist in end-stage kidney disease: Are they safe and effective?

Observational Studies

The gut microbiota modulate locomotion via vagus-dependent glucagon-like peptide-1 signaling

Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels

Monitoring Report: GLP-1 RA Prescribing Trends - December 2023 Data (a bit late, but better late than never)

Cellular mechanisms of incretin hormone secretion

GLP-1 in patients with myocardial infarction complicated by cardiogenic shock—an IABP-SHOCK II-substudy

The Effects of a High-Carbohydrate versus a High-Fat Shake on Biomarkers of Metabolism and Glycemic Control When Used to Interrupt a 38-h Fast: A Randomized Crossover Study


All cause mortality reduction

Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes

(Meta-analysis) GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis

Reduction in Colorectal Cancer

(Commentary) Potential role of glucagon like peptide (GLP)-1 receptor agonist to reduce risk of colorectal cancer?

Cardiovascular Benefits

(Meta-analysis) Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients

Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease: Underuse of GLP-1RAs in patients with ASCVD

(Meta-analysis) GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis

Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials

Prevention of cardiorenal complications in people with type 2 diabetes and obesity

Post gastric bypass benefits

Brain-gut-adipose interplay in the antidiabetic effects of gastric bypass surgery

Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes

Confirmation of A1c & Body Weight reduction

Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study

Myocardial Infraction ("heart attack") risk reduction

Effects of albiglutide on myocardial infarction and ischemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial

GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes

Reduction of suicidal thoughts

Association of semaglutide with risk of suicidal ideation in a real-world cohort

Stroke Prevention

Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis

Cognitive Performance

Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension

The Effect of Liraglutide on Axon Regeneration and Functional Recovery after Peripheral Nerve Lesion

GLP-1 derivatives with functional sequences transit and migrate through trigeminal neurons

Nerve damage reversal

Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy

Sleep Apnoea

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review

Post-liver transplant weight gain

Biguanides and Glucagon Like Peptide 1 Receptor Agonists in the Amelioration of Post Liver Transplant Weight Gain; A Scoping Review of the Mechanism of Action, Safety and Efficacy


Bone density

Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures

Renal (kidney) outcomes

(Meta-analysis) Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data

(Meta-analysis) Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis

Confirmation of glycaemic control in type 2 diabetes

(Meta Analysis) Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

Increase in required fasting times pre-operation

Undigested food found in a patient undergoing surgery after no food for 24 hrs

Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration

Aspiration risk with long-acting GLP-1 RAs

Benefits for pre-operation patients suffering from Diabetes Mellitus

Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus

Retinal Disease

Neuroprotective effects of GLP-1 receptor agonists and their potential in retinal diseases


Gastric POCUS compared to preemptive RSI for GLP-1 receptor agonist management

Inflammatory Bowel Disease

Do glucagon-like peptide-1 based therapies alter the risk of late-onset inflammatory bowel disease?



(In mice) Maternal GLP-1 receptor activation inhibits fetal growth

Suicidality among users of GLP1

(Commentary) Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?

(See: the research that directly contradicts this commentary)

Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database

Pulmonary aspiration (lung infection from introduction of foreign contents) in patients on GLP1

Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss

Psychiatric Adverse Events

Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database

Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database

Allergic Reactions

A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide

Existing Conditions

Diabetes Mellitus

Association of GLP-1 secretion with parameters of glycemic control in women after gestational diabetes mellitus

Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus

Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies

Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies

Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study


First Large Study of GLP-1 Receptor Agonists During Pregnancy


(Meta-analysis) The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity

Hypothalmic Obesity

The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity—A systematic review

Note the stated conflict of interest in the hypothalmic obesity-related study above

New methods/approaches/substances

Cagrilintide and Semaglutide ("CagrAndSema")

(Meta Analysis) Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis

Cotadutide (GLP1 + GCG)

Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis

Probiotic Lactobacillus plantarum H-72 for stimulating GLP1

Profiles of Intestinal Flora in Breastfed Obese Children and Selecting Functional Strains Against Obesity

β-lactoglobulin (whey protein from cows/sheep)

Effects of physical form of β-lactoglobulin and calcium ingestion on GLP-1 secretion, gastric emptying and energy intake in humans; a randomised crossover trial

Continuous infusion

Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial

Nanoparticle usage for improved delivery

Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide

Engineered bacteria that expresses GLP1

Biochemotaxis-Oriented Engineering Bacteria Expressing GLP-1 Enhance Diabetes Therapy by Regulating the Balance of Immune

Olive Seed to boost GLP1 secretion

Olive (Olea europaea L.) Seed as New Source of Cholesterol-Lowering Bioactive Peptides: Elucidation of Their Mechanism of Action in HepG2 Cells and Their Trans-Epithelial Transport in Differentiated Caco-2 Cells


Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals

Preserving muscle mass

Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism

Ferulic Acid

Ferulic acid reduces GLP-1 degradation to ameliorate diet-induced obesity-associated hepatic steatosis

📬 Get the latest GLP1 news straight to your inbox